1-7 of 7
Susan Lattimore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

End-of-study analysis of the HOPE-B trial confirms the durable efficacy and safety of etranacogene dezaparvovec hemophilia b gene therapy over 5 years

Free
Steven Pipe, Wolfgang Miesbach, Michael Recht, Frank Leebeek, Nigel Key, Giancarlo Castaman, Susan Lattimore, Michiel Coppens, Sandra LeQuellec, Sean Gill, Vaibhav Mahajan, Douglass Drelich, Paul Monahan
Journal: Blood
Blood (2025) 146 (Supplement 1): 538.
https://doi.org/10.1182/blood-2025-538
Published: 2025
Journal Articles

Management of hemophilia and hemophilia carriers

Free
Susan Lattimore, Kristina Haley
Journal: Blood
Blood (2025) 146 (Supplement 1): 6619.
https://doi.org/10.1182/blood-2025-6619
Published: 2025
Journal Articles

Patient Satisfaction at United States Hemophilia Treatment Centers in 2023

Free
Susan Lattimore, Eleanor Carrick, Heather MacFarlane, Virginie Sirianna, Nicole Crook
Journal: Blood
Blood (2024) 144 (Supplement 1): 3698.
https://doi.org/10.1182/blood-2024-197994
Published: 2024
Journal Articles

Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

Free
Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, Michiel Coppens, David Cooper, Robert Gut, Sergio Slawka, Stephanie Verweij, Ricardo Dolmetsch, Yanyan Li, Paul E. Monahan, Wolfgang A. Miesbach
Journal: Blood
Blood (2022) 140 (Supplement 1): 4910–4912.
https://doi.org/10.1182/blood-2022-166135
Published: 2022
Journal Articles

Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

Free
Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, David Cooper, Stephanie Verweij, Ricardo Dolmetsch, Jacqueline Tarrant, Yanyan Li, Paul E. Monahan, Wolfgang A. Miesbach
Journal: Blood
Blood (2022) 140 (Supplement 1): 4904–4906.
https://doi.org/10.1182/blood-2022-166745
Published: 2022
Journal Articles

Decreased Skeletal Health Negatively Impacts Quality of Life of People with Hemophilia

Free
Galen Goldscheitter, BS, BA, Susan Lattimore, Jason A Taylor, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1207.
https://doi.org/10.1182/blood-2018-99-113086
Published: 2018
Journal Articles

Identification of Qualitative Platelet Disorders in Adolescent Women with Heavy Menstrual Bleeding

Free
Kristina M. Haley, DO, Susan Lattimore, RN, Cara McDavitt, Ayesha Khader, Colin Boehnlein, Sandra Baker-Groberg, PhD, Anh Ngo, Owen J.T. McCarty, PhD, Michael Recht, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4922.
https://doi.org/10.1182/blood.V128.22.4922.4922
Published: 2016